We aim in this study to provide levels of susceptibility of 162 bloodstream isolates of non-Candida albicans and non-C. tropicalis species from a sentinel program conducted in 11 hospitals in Brazil. Additionally, we compared the broth microdilution (BMD) method of the European Committee of Susceptibility Testing (EUCAST) with Clinical Laboratory Standards Institute (CLSI) BMD method for fluconazole, itraconazole, voriconazole, and amphotericin B. The study included 103 C. parapsilosis, 38 C. glabrata, 8 C. orthopsilosis, and 7 C. krusei isolates, and single isolates of Pichia anomala, C. famata, C. lusitaniae, C. kefyr, C. guilliermondii, and C. metapsilosis. Of note, we observed cross-resistance between fluconazole and voriconazole for two isolates being one C. parapsilosis and one C. glabrata. Good essential agreement (EA) was observed between the EUCAST and the CLSI results for C. parapsilosis and for fluconazole, itraconazole, voriconazole, and amphotericin B, respectively: 98%, 99%, 98%, and 97%. Otherwise, for C. glabrata, the EA for fluconazole was 84.2% and for voriconazole 89.4%. Because data from Brazil are scarce, our results contribute to the consolidation of the database of candidemia agents and monitoring of trends in the profile of drug resistance.
Introduction
Candidemia has great significance, given its high mortality rate (31.8-50%), and increased hospital costs for its control (Patel et al., 2005; Pfaller & Diekema, 2007) . Clinical course depends on several factors including patient, APACHE score, immunosuppressive therapy, antifungal strategy, and causative agents, among others (Andes et al., 2012) . Candida albicans remains the most common agent isolated from bloodstream infections (BSI) in many parts of the world although a global shift in epidemiology toward the non-C. albicans species has been described Eggimann et al., 2003; Nakamura & Takahashi, 2006; Sobel, 2006; Ruan et al., 2008; Horn et al., 2009; Leroy et al., 2009; Pfaller et al., 2011a) . These trends are of concern, because species exhibit variable susceptibility to antifungal drugs (Bader et al., 2004; Fourrier et al., 2005; Messer et al., 2009) . Candida tropicalis is the second most frequent agent in some countries, according to previous data (Godoy et al., 2003; Pfaller et al., 2004; Nakamura & Takahashi, 2006; da Matta et al., 2007) . Candida parapsilosis and C. glabrata complex species may vary in resistance characteristics and are frequent as BSI agents (Lockhart et al., 2008; Tay et al., 2009) .
Nowadays, there are several methods to perform these susceptibility assays. Standardized methods have been published by Clinical Laboratory Standards Institute (CLSI, 2008) and Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST, 2008c) . Both methodologies have defined 24-h-wild-type MIC distributions and epidemiological cutoff values for the most common species of Candida (Pfaller et al., 2010; EUCAST, 2008a) .
We conducted a study to analyze bloodstream isolates of Candida species including genotyping C. parapsilosis complex and C. glabrata complex by PCR-RFLP. Additionally, we tested fluconazole, itraconazole, voriconazole, and amphotericin B using the CLSI and EUCAST broth microdilution (BMD) methods and determined the essential agreement (EA) and categorical agreement (CA) between the two methodologies when applied.
Materials and methods

Clinical isolates
The isolates were obtained from eleven hospitals located in the state of São Paulo, Brazil, from January 2005 to December 2008, during a sentinel program encompassing 473 candidemia agents corresponding to one isolate per patient. The study was conducted at the laboratories of Adolfo Lutz Institute, which serves as a reference center for the surveillance of fungal infections. All of 162 isolates identified as non-C. albicans and non-C. tropicalis were tested for this study. The isolates were stored at À20°C in 15% glycerol and were thawed and subcultured onto antimicrobial-free medium to ensure viability and purity prior to identification and antifungal testing.
Antifungal susceptibility testing
All 162 isolates were tested three times for in vitro susceptibility to fluconazole, itraconazole, voriconazole, and amphotericin B according to the CLSI (2008) and the EUCAST (2008a) . The following reference powders of each agent were obtained from their respective manufacturers: fluconazole and voriconazole (Pfizer Central Research, New York, NY), itraconazole (Janssen, Beerse, Belgium), and amphotericin B (Sigma-Aldrich Chemical, SA). The two methods are similar, but they differ in inoculum density (0.5 9 10 3 -2.5 9 10 3 CFU mL À1 for CLSI and 0.5 9 10 5 -2.5 9 10 5 CFU mL À1 for EUCAST), The recently revised CLSI and EUCAST clinical breakpoints were used to identify strains of Candida that were resistant to fluconazole and voriconazole when applied (Pfaller et al., 2010 (Pfaller et al., , 2011b EUCAST, 2008a, b) . All isolates with MIC > 1 mg L À1 for amphotericin B obtained through any of two methods were considered resistant (Diekema et al., 2009 ; European Committee on Antimicrobial Susceptibility Testing, 2010). The EA (discrepancies of no more than ± 2 log dilutions) between the two methods were calculated. The CA between both methods was accessed for amphotericin B, fluconazole, and voriconazole results.
DNA extraction
Each isolate was plated on Sabouraud dextrose agar and incubated at 30°C for 24 h. The yeast cells were transferred to a microcentrifuge tube containing 1 mL of 50 mM EDTA (Sigma Chemical), pH 8.0, mixed, and centrifuged at 13 000 g for 15 min. The supernatant was removed, and the pellet was resuspended in 200 lL of 50 mM EDTA, pH 8.0, containing 40 lL of lysing enzyme from Trichoderma harzianum (10 mg mL À1 ; Sigma Chemical), and then incubated at 37°C for 2-3 h. Subsequently, this mixture was centrifuged at 13 000 g for 10 min, and the pellet was dissolved in lysis buffer containing 10 mM Tris-HCl, pH 8.0; 10 mM EDTA, pH 8.0; 0.5% sodium dodecyl sulfate (SDS); 0.01% N-laurilsarcosyl; and 100 mg L À1 proteinase K. The mixture was vortex mixed and incubated at 56°C for 2-3 h. DNA was extracted using a phenol/chloroform/isoamylalcohol method according to Sambrook et al., 1989 . After washing with 70% ethanol for 10 min at 10 000 g, the DNA was dried and re-suspended in 50 lL of ultrapure water. DNA concentrations were determined with a NanoDrop 1000 apparatus (Thermo Fisher Scientific). The DNA template was adjusted to a concentration of approximately 100 ng lL À1 and frozen at À20°C for later use.
Strain-type cultures of C. parapsilosis ATCC 22019, C. metapsilosis ATCC 96143, C. orthopsilosis ATCC 96139, and C. glabrata ATCC 90030 were included in all tests.
Green Master Mix kit; Promega). Genomic DNA template (approximately 100 ng lL À1 ) and 25 pmol of individual primer pairs were added to this mixture to a final volume of 25 lL. For C. glabrata, the protocol used was described by Luo & Mitchell (2002) . The following primer pair was used: CGL1 (5′-TTATCACACGACTCGACACT-3′) and CGL2 (5′-CCCACATACTGATATGGCCTACAA3′; Invitrogen, Life Technologies, Brazil). The PCR amplification conditions were 5 min of denaturation at 94°C, followed by 40 cycles at 94°C for 30 s, 58°C for 30 s, and 72°C for 30 s, with a final extension step at 72°C for 10 min. For the C. parapsilosis complex, the protocol used was described by Tavanti et al., 2005 . To amplify the secondary alcohol dehydrogenase (SADH) fragment, the following primer pair was used: S1F (5′-GTTGATGCTGTTGGATTGT-3′) and S1R (5′-CAATGCCAAATCTCCCAA-3′; Invitrogen). The amplification conditions were 5 min of denaturation at 94°C, followed by 30 cycles at 94°C for 45 s, 50°C for 1 min, and 72°C for 45 s, with a final extension step of 10 min at 72°C. The amplification product consisting of SADH fragments was digested for 90 min with BshNI (Fermentas, Life Sciences, Canada) in a 20-lL reaction volume containing 6 lL of PCR product, 4 mL of 109 buffer O (supplied with enzyme), and 2 lL of 20 U BshNI (BanI lL
À1
).
Electrophoresis
All amplified DNA products and digestion products were separated by electrophoresis in a 2% agarose gel in running buffer TBE (0.044 M Tris-borate, 0.001 M EDTA pH 8.0) at 100 V for 35 min, and a 100 bp DNA ladder was used as a molecular size marker (Invitrogen, Brazil).
The gel was stained with ethidium bromide (0.5 mg mL À1 ), and DNA bands were visualized on a UV transilluminator and documented with a Mini Bis Pro (Bio-Imaging Systems, Ltd., Israel). Clinical isolates were discriminated as C. glabrata, C. parapsilosis, C. orthopsilosis, and C. metapsilosis according to the PCR and the SDAH restriction profile.
Results
Among 162 isolates of non-C. albicans and non-C. tropicalis candidemia agents, we found 103 (63.6%) of C. parapsilosis stricto sensu, 38 (23.4%) of C. glabrata, 8 (5%) of C. orthopsilosis, and 7 (4.4%) of C. krusei isolates, in addition to a single (0.6%) isolate of the following species: C. metapsilosis, C. lusitaniae, C. famata, C. pelliculosa, C. guilliermondii, and C. kefyr. Neither C. bracarensis nor C. nivariensis were identified among the C. glabrata strains using molecular tools. The overall EA between the EUCAST and CLSI methods were as follow: fluconazole (94.3%), itraconazole (97.1%), voriconazole (95.7%), and amphotericin B (97.1%). For C. parapsilosis isolates the CA was 100% for both amphotericin B and voriconazole. For the remaining species the CA was 99% for fluconazole.
The following results are for a single isolate of the given species, according to the MIC values of fluconazole, itraconazole, voriconazole, and amphotericin B by both methodologies (EUCAST/CLSI). Candida famata (0.5/0.5 mg L 
Discussion
Although national and international surveillance is crucial to recognize trends in drug resistance, it is also of utmost importance to gain knowledge about the local antifungal susceptibility pattern because this information should guide the empiric therapy of patients (Rodloff et al., 2011 ). An increasing number of infections because of non-C. albicans species has been reported in Brazilian studies (Medrano et al., 2006; Chang et al., 2008; BruderNascimento et al., 2010; Passos et al., 2010; Pereira et al., 2010) . These studies provide us with valuable information concerning the etiology of candidemia because official data from our country, and particularly from the state of São Paulo, are limited. This is a serious problem, given the number of existing hospitals (approximately 900) in the state (Epidemiology Surveillance Center -CVE, 2010). To date, there are no extensive data available regarding the therapeutic and prophylactic use of fluconazole in Brazilian hospitals, but it is unlikely to be the primary cause of the emergence of resistant strains among candidemia agents as we observed in eleven nosocomial units. Our data emphasize a low number of infections because of non-C. albicans species with innate (C. krusei) or acquired (C. glabrata) resistance to fluconazole as well as cross-azole resistance among Candida species isolates.
Interestingly, itraconazole exhibited reduced activity against two high-fluconazole-MIC (MIC 64 mg L À1 )
isolates of C. glabrata, a intrinsically low-azole-susceptible species (Vermitsky & Edlind, 2004) . Cross-resistance to Fluconazole susceptibility categories for 48-h CLSI BMD: C. albicans, C. parapsilosis, and C. tropicalis, S,
. Voriconazole susceptibility categories for 48-h CLSI BMC: for all species S,
. Fluconazole susceptibility categories for 24-h EUCASTI BMD: C. albicans, C. parapsilosis, and
; Voriconazole susceptibility categories for 24-h EUCAST BMC: C. albicans, C. parapsilosis, and C. tropicalis, S, 0.125 mg L À1 , R, > 0.125 mg L
À1
. *For a total of 141 isolates of C. glabrata and C. parapsilosis NA, not applied for < 10 isolates; NT, not tested; considered to be intrinsically resistant to fluconazole. Non-C. albicans and non-C. tropicalis isolates susceptibility azoles, particularly, between fluconazole and itraconazole has been observed through the literature (Tiez et al., 1999; Chakrabarti et al., 2009; Savini et al., 2010) . It was notable that isolates of C. parapsilosis and C. glabrata, expressing fluconazole and voriconazole resistance, were described in our study. Although the C. parapsilosis complex is usually susceptible to antifungal agents, with few reports of isolates showing decreased susceptibility to azoles, differences in antifungal susceptibility among the three cryptic species have been observed (Moudgal et al., 2005; Miranda-Zapico et al., 2011) . In contrast with our findings, fluconazole-MICs for C. metapsilosis isolates were high in early studies (Lockhart et al., 2008; Chen et al., 2010; Gonçalves et al., 2010) . In contrast to data published by Miranda-Zapico (2011), we did not observe unusually high itraconazole-MIC for C. parapsilosis stricto sensu isolates, and also, we reported no resistance among C. metapsilosis and C. orthopsilosis strains.
The high susceptibility to amphotericin B for all tested isolates was predictable, because BMD methods produce results within a narrow range (0.5-1 mg L À1 ; CLSI, http://www.clsi.org; Gonçalves et al., 2010; Del Toro et al., 2011) . Few reports could demonstrate less susceptibility to this drug in C. parapsilosis clinical isolates (Gomez-Lopez et al., 2008; Lockhart et al., 2008) . The susceptibilities were accessed and interpreted with the EUCAST and CLSI BMD methods when available. The controversial or nonexistent interpretative breakpoints of CLSI and EUCAST BMD for some species-drug pairs remain a concern for the assessment of the CA. An excellent CA was observed for the achievable comparisons between the CLSI and EUCAST methods, confirming previous data (Pfaller et al., 2011c) . We emphasize that the EA varied depending on the species, being the EA for fluconazole and C. glabrata the lowest (84.2%) in contrast with previous data reporting values as high as 97.7% (Pfaller et al., 2010) . The EA for voriconazole in tests with C. glabrata (89.4%) was also lower in comparison with early data (93.1%). The results for C. glabrata may be quite variable and could represent a technical problem, as documented in tests with fluconazole (Arendrup et al., 2009) .
We described in this four-year study (2005) (2006) (2007) (2008) ) the results of ten species aside from C. albicans and C. tropicalis, which were isolated from eleven hospitals, and indicated the value of an information database for empirical management and control of candidemia cases. We confirmed the low prevalence of the recently described species C. orthopsilosis and C. metapsilosis among samples of blood culture isolates. We could not demonstrate alarming tendencies in the susceptibility profile of species such as C. glabrata, C. krusei, and C. lusitaniae, which deserve special attention because of their high potential for acquired or intrinsic resistance to azoles and lower susceptibility to amphotericin B. Accurate determination of endemic and epidemic species and the investigation of resistance phenotypes could be used for monitoring trends in clinical isolates from distinct geographic regions.
